

**Sun Pharmaceutical Industries Ltd.**

Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai - 400 063, Maharashtra, India.  
Tel. : (91-22) 4324 4324  
Fax.: (91-22) 4324 4343  
Website : www.sunpharma.com  
CIN : L24230GJ1993PLC019050



May 09, 2022

National Stock Exchange of India Ltd,  
Exchange Plaza, 5th Floor,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East), Mumbai – 400 051.  
NSE Code – SUNPHARMA

BSE Ltd,  
Market Operations Dept.  
P. J. Towers, Dalal Street,  
Mumbai - 400 001.  
BSE Code– 524715


**Sub: Submission of Annual Disclosure for FY 2021-22**

Dear Sirs,

The Company does not fall under the definition of “Large Corporate”. A declaration to this effect was submitted on April 12, 2021.

Further to the declaration mentioned above, please find enclosed herewith the Annual Disclosure for FY 2021-22, in Annexure –1, as required pursuant to clause 4.1 (ii) of SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018, which, otherwise is applicable only to Large Corporate.

**For Sun Pharmaceutical Industries Limited**

  
(Anoop Deshpande)

**Company Secretary & Compliance Officer**

## Sun Pharmaceutical Industries Ltd.

Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai - 400 063, Maharashtra, India.  
Tel. : (91-22) 4324 4324  
Fax.: (91-22) 4324 4343  
Website : www.sunpharma.com  
CIN : L24230GJ1993PLC019050



### Annexure-1

#### Annual Disclosure to be made by an entity identified as a LC

1. Name of the Company : **Sun Pharmaceutical Industries Limited**
2. CIN : **L24230GJ1993PLC019050**
3. Report filed for FY : **(T) 2021-22**
4. Details of the Current block (all figures in Rs crore):

S. No.	Particulars	Details
i.	2-year block period (Specify financial years)	<b>FY 2021-22 (T), FY 2022-23 (T+1)</b>
ii.	Incremental borrowing done in FY (T) (a)	0.00*
iii.	Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)	Not Applicable
iv.	Actual borrowing done through debt securities in FY (T) (c)	Not Applicable
v.	Shortfall in the borrowing through debt securities, if any, for FY (T-1) carried forward to FY (T). (d)	Not Applicable
vi.	Quantum of (d), which has been met from (c) (e)	Not Applicable
vii.	Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) {after adjusting for any shortfall in borrowing for FY (T-1) which was carried forward to FY (T)} (f) = (b)-[(c)-(e)] <b>{If the calculated value is zero or negative, write "nil"}</b>	Not Applicable

\*Note: "borrowing" as defined in SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018

5. Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore):

S. No.	Particulars	Details
i.	2-year Block period (Specify financial years)	<b>FY2020-21 (T-1) FY2021-22 (T)</b>
ii.	Amount of fine to be paid for the block, if applicable <b>Fine = 0.2% of {(d)-(e)}#</b>	Not Applicable

**Sun Pharmaceutical Industries Ltd.**

Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai - 400 063, Maharashtra, India.  
Tel. : (91-22) 4324 4324  
Fax.: (91-22) 4324 4343  
Website : www.sunpharma.com  
CIN : L24230GJ1993PLC019050



**For Sun Pharmaceutical Industries Limited**

**C. S. Muralidharan**  
**Chief Financial Officer**  
Contact No: 022 4324 2121

**Anoop Deshpande**  
**Company Secretary & Compliance Officer**  
Contact No: 022 4324 4324

Date - 09/May/2022

\$ - In cases, where an entity is not categorised as LC for FY (T), however was LC for FY (T-1), and there was a shortfall in the mandatory bond borrowing for FY (T-1), which was carried forward to FY (T), the disclosures as prescribed in this annexure shall be made by the entity for FY (T).

#- (d) and (e) are same as mentioned at 4(v) and 4(vi) of this annexure.